Database Query Results : , , UroPA

UroPA, Urokinase plasminogen activator: Click to Expand ⟱
Source: HalifaxProj (suppress)
Type:
Urokinase plasminogen activator (uPA) is an enzyme that plays a significant role in the process of fibrinolysis, which is the breakdown of fibrin in blood clots. It is involved in the conversion of plasminogen to plasmin, leading to the degradation of fibrin and other components of the extracellular matrix. This process is crucial in various physiological and pathological conditions, including wound healing and tissue remodeling.
Elevated levels of uPA and uPAR in tumor tissues and bodily fluids (such as serum) have been associated with a poor prognosis in several types of cancer, including breast, ovarian, and colorectal cancers. The rationale is that increased uPA activity can facilitate tumor cell invasion through the degradation of the extracellular matrix, allowing cancer cells to spread to other tissues.
Scientific Papers found: Click to Expand⟱

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 0

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: UroPA, Urokinase plasminogen activator
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:332  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page